Women are commonly screened for osteoporosis at age 65 years. How should screening for osteoporosis be managed in a male this age?

Prepare for the APEA Management Orthopedics Test using flashcards and multiple choice questions, complete with hints and explanations for effective learning. Gear up for your test now!

Multiple Choice

Women are commonly screened for osteoporosis at age 65 years. How should screening for osteoporosis be managed in a male this age?

Explanation:
The main idea is that osteoporosis screening in men at age 65 is not done routinely for all men; it’s recommended when there are risk factors that raise fracture risk. Men do develop osteoporosis, and age increases fracture risk, but universal screening at 65 isn’t the standard. If a 65-year-old man has risk factors—such as a prior fragility fracture, chronic glucocorticoid use, low body weight, hypogonadism or low testosterone, smoking, heavy alcohol use, or certain chronic diseases—the next step is to perform bone density testing (DXA) and assess fracture risk (often with FRAX). This targeted approach helps identify those who would benefit from treatment to prevent fractures. Prostate disease by itself isn’t a screening trigger; however, therapies for prostate cancer that reduce testosterone can increase bone loss, which would then influence screening decisions.

The main idea is that osteoporosis screening in men at age 65 is not done routinely for all men; it’s recommended when there are risk factors that raise fracture risk. Men do develop osteoporosis, and age increases fracture risk, but universal screening at 65 isn’t the standard. If a 65-year-old man has risk factors—such as a prior fragility fracture, chronic glucocorticoid use, low body weight, hypogonadism or low testosterone, smoking, heavy alcohol use, or certain chronic diseases—the next step is to perform bone density testing (DXA) and assess fracture risk (often with FRAX). This targeted approach helps identify those who would benefit from treatment to prevent fractures. Prostate disease by itself isn’t a screening trigger; however, therapies for prostate cancer that reduce testosterone can increase bone loss, which would then influence screening decisions.

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy